Over the last decade, the study of comorbidities has generated great interest in the development of better etiology, prevention and treatment models. However, several interpretational caveats have been raised concerning the fmdings so far. These methodological factors have recently been summarized in a comprehensive review to the US Congress of the research in the alcohol field (l), the most noteworthy including:
1. The chance overlap in the prevalence of common disorders: the extent of comorbidity among common diseases such as anxiety, mood and substance use disorders results in a need to differentiate between "statistical significance" where the presence of one disorder further increases the risk of another disorder, and "clinical significance" where the co-occurrence, independent of risk, alters the clinical course or optimal treatment of either condition. 2. The overlap of diagnostic criteria between disorders: different diagnostic methods produce different comorbidity rates, with the structured diagnostic interviews being considered the most reliable. Inflated comorbidity rates can be obtained using several DSM diagnostic criteria where overlapping symptoms can be counted towards the diagnosis of more than one comorbid condition. For example, the inability to sustain social obligations is a criterion for both substance use and antisocial personality disorders. Substance use disorders are also known to produce transient symptoms mimicking independent psychiatric syndromes that may be difficult to control in surveys. 3. The sampling effect: clinical samples will yield higher comorbidity rates than community samples as people with two or more conditions are more likely to enter treatment than people with one disorder. 4. The nature ofthe association between disorders: studying the sequence of onset of comorbid disorders necessitates the need to control for errors associated with the informant's mistaken memory or misrepresentation. Whenever possible, a prospective design is preferable. Studies investigating shared etiology between disorders of a familial or genetic nature have so far concluded that this was unlikely. However, the presence of antisocial behaviour in a family may increase the relatives' risk towards alcoholism because antisocial behaviour may include drinking and a vulnerability to alcohol-related problems.
Despite the commonsense appeal of a self-medication hypothesis and the fact that patients, retrospectively, will often believe that alcohol provides relief from symptoms oftheir conditions as apost hoc rationalization for drinking, substances used may both increase and decrease psychiatric symptoms. A prospective design may again help investigate factors underlying the onset and maintenance of comorbid conditions. 5. The relative impact on clinical course-findings across studies indicates that patients with comorbid conditions experience a worse course in their conditions compared to patients with one disorder. However, simple causeand-effect relationships between the co-occurrence of specific clinical conditions such as depression and alcoholism have been more difficult to identify. The need to subtype comorbid patients, along such variables as relative onset of diseases, presence or absence of antisocial personality, has been suggested. A major investigative problem in the study of the course of illness lies in the considerable shifts in patterns of symptoms recorded among comorbid patients resulting from increased use or discontinuation of substances. 6. The relative efficacy of different treatment priorities and strategies: so far the study of the efficacy of hybrid treatments advocated by clinicians who are involved in the management of comorbidities has been hampered by such difficulties as the challenges of engagement and retention presented by the patients, the reluctance of the pharmaceutical industry to test their products with these populations and the design concerns raised by multimodal approaches to treatment.
In the context ofthe above methodological framework, the importance of the paper by Links et al (2) presented in this issue can be assessed. This study adds to the literature investigating the co-occurrence of borderline personality disorder (BPD) and substance abuse among clinical samples. It provides, to my knowledge, unique longitudinal insight into the added impact of substance abuse on the clinical course of this volatile group of patients over seven years. After being first admitted to hospital at a younger age, comorbid patients as compared to noncomorbid patients are twice as likely to be rediagnosed as BPD seven years later and to carry evidence of suicidal thoughts and behaviour. As expected, a high proportion ofBPD patients who are substance abusers are also lost to follow-up. The authors also present compelling evidence for targettingthe initialmanagementeffortstowards the problem of substance abuse.
This study adds to the small body ofevidence which so far suggests that among personality disorders, the borderline group may, in addition to the antisocial group, identify substance abusers for whom the poorer clinical course is to be predicted. The relevance of antisocial personality disorder as a predictor of alcoholism is well acknowledged in recent studies (3) that investigate personality profiles associated with an individual's risk of alcoholism. The work of Links et al (2) provides further evidence that the cluster of borderline symptoms deserve further recognition as risk factors.
Lastly, as Canadian psychiatristscontinueto struggle with the importance that is to be granted to the management of substance abuse as a meaningful component of our training programs and practices, this study highlights the pervading impact of substance abuse on the course and management of one ofthe most challenging groups of patients.
